Acadia Pharma Reports Executive Compensation Changes
Ticker: ACAD · Form: 8-K · Filed: 2024-01-31T00:00:00.000Z
Sentiment: neutral
Topics: executive-compensation, corporate-governance, 8-K
TL;DR
**Acadia Pharma just updated executive pay, watch for strategic shifts.**
AI Summary
Acadia Pharmaceuticals Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024, related to changes in its executive compensation arrangements. This filing, under Item 5.02, indicates potential shifts in how the company incentivizes its leadership, which could impact future financial performance and shareholder value. Investors should note these changes as they reflect the company's strategy for retaining and motivating key personnel.
Why It Matters
Changes in executive compensation can signal shifts in company strategy or financial health, directly influencing how top management is motivated to perform and potentially affecting long-term stock performance.
Risk Assessment
Risk Level: low — This filing is purely informational regarding executive compensation and does not indicate immediate financial distress or operational risk.
Analyst Insight
A smart investor would monitor subsequent filings or press releases for specific details on the new compensatory arrangements to understand their potential impact on executive incentives and company strategy.
Key Players & Entities
- Acadia Pharmaceuticals Inc. (company) — the registrant filing the 8-K
- January 30, 2024 (date) — date of the earliest event reported
- January 31, 2024 (date) — date the 8-K was filed
- 000-50768 (number) — Commission File Number for Acadia Pharmaceuticals Inc.
- ACAD (company) — trading symbol for Acadia Pharmaceuticals Inc.
FAQ
What was the specific item reported in this 8-K filing by Acadia Pharmaceuticals Inc.?
Acadia Pharmaceuticals Inc. reported an event under Item 5.02, titled 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', on January 30, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 30, 2024.
What is the trading symbol for Acadia Pharmaceuticals Inc.?
The trading symbol for Acadia Pharmaceuticals Inc. is ACAD, and its common stock is registered on The Nasdaq Stock Market LLC.
What is the business address of Acadia Pharmaceuticals Inc. as stated in the filing?
The business address of Acadia Pharmaceuticals Inc. is 12830 El Camino Real, Suite 400, San Diego, California, 92130.
Under which SEC Act was this 8-K filed?
This 8-K was filed under the 1934 Act, as indicated by the 'SEC ACT: 1934 Act' in the filing values.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 12.5 · Accepted 2024-01-30 21:55:00
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- d113006d8k.htm (8-K) — 23KB
- 0001193125-24-019903.txt ( ) — 141KB
- acad-20240130.xsd (EX-101.SCH) — 3KB
- acad-20240130_lab.xml (EX-101.LAB) — 18KB
- acad-20240130_pre.xml (EX-101.PRE) — 11KB
- d113006d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acadia Pharmaceuticals Inc. Dated: January 30, 2024 By: /s/ Austin D. Kim Austin D. Kim Executive Vice President, General Counsel & Secretary